^
    4d
    Co-SAM: An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (clinicaltrials.gov)
    P3, N=674, Active, not recruiting, Queen Mary University of London | Recruiting --> Active, not recruiting | N=1266 --> 674 | Trial primary completion date: Jul 2026 --> Feb 2026
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    rifampicin
    6d
    P1-IMU838DDI-CYP2C8: A Phase 1, Single-Center, Open-Label, Fixed-Sequence, 2-Part Study to Assess the Pharmacokinetics of IMU-838 Administered Alone and in Combination with Multiple Doses of Gemfibrozil as CYP2C8 Inhibitor, or Rifampicin as CYP2C8 Inducer, in Healthy Subjects (2025-521754-41-00)
    P1, N=24, Active, not recruiting, Immunic AG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    rifampicin
    10d
    Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery (clinicaltrials.gov)
    P=N/A, N=60, Enrolling by invitation, Shaukat Khanum Memorial Cancer Hospital & Research Centre
    New trial
    |
    rifampicin
    10d
    Drug Interaction and Food Effect Study of CS0159 (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Cascade Pharmaceuticals, Inc
    New P1 trial
    |
    itraconazole • rifampicin
    11d
    Differential gene regulation by SR12813 and rifampicin: Insights into PXR and PPARγ activation and metabolic pathway modulation in LS180 colon cancer cells. (PubMed, Drug Metab Dispos)
    SIGNIFICANCE STATEMENT: SR12813 activates both pregnane X receptor and peroxisome proliferator-activated receptor gamma, demonstrating dual nuclear receptor modulation in colon cancer cells. By linking xenobiotic metabolism with lipid and mitochondrial pathways, this work uncovers previously unreported receptor crosstalk and provides a mechanistic framework for how diverse ligands can differentially shape transcriptional programs relevant to drug metabolism and tumor biology.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • NR1I2 (Nuclear Receptor Subfamily 1 Group I Member 2)
    |
    rifampicin
    12d
    Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours (clinicaltrials.gov)
    P1, N=64, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Recentin (cediranib) • rifampicin
    12d
    PRESCIENT: Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB (clinicaltrials.gov)
    P2, N=94, Active, not recruiting, Brigham and Women's Hospital | N=156 --> 94
    Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    rifampicin
    17d
    RC24_0404: Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter randomized controlled non-inferiority study (RIFREE) (2024-518018-22-00)
    P2/3, N=422, Not yet recruiting, Centre Hospitalier Universitaire De Nantes
    New P2/3 trial • Head-to-Head
    |
    rifampicin
    22d
    Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus (clinicaltrials.gov)
    P3, N=162, Completed, University Hospital, Tours | Recruiting --> Completed | N=324 --> 162
    Trial completion • Enrollment change
    |
    rifampicin
    24d
    PRESCIENT: Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB (clinicaltrials.gov)
    P2, N=156, Active, not recruiting, Brigham and Women's Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    rifampicin
    24d
    PRiMe: Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, McGill University Health Centre/Research Institute of the McGill University Health Centre | Initiation date: Oct 2025 --> Apr 2026
    Trial initiation date
    |
    rifampicin
    25d
    Shorter and Safer Treatment Regimens for Latent TB (clinicaltrials.gov)
    P2/3, N=1800, Recruiting, McGill University Health Centre/Research Institute of the McGill University Health Centre | Not yet recruiting --> Recruiting
    Enrollment open
    |
    rifampicin